metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-4 HYPOTHERMIC OXYGENATED PERFUSION USING AN ECMO DEVICE IN LIVER TRANSPLANTATI...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Full text access
P-4 HYPOTHERMIC OXYGENATED PERFUSION USING AN ECMO DEVICE IN LIVER TRANSPLANTATION: AN ANALYSIS OF THE FIRST 100 CASES AT A CHILEAN PUBLIC HOSPITAL
Visits
27
FRANCISCA MAGDALENA MARTÍNEZ VENEZIAN1, Elizabeth Rivas2, Valeria Galaz3, Valentina Castillo2, Julio Benitez3, Edmundo Martinez3, Rodrigo Wolff3, Blanca Norero3, Erwin Buckel3, Rolando Rebolledo4
1 Pontificia Universidad Católica de Chile, Santiago, Chile
2 Instituto de Ingenieria Biologica y Medica/Pontificia Universidad Católica de Chile, Santiago, Chile
3 Hospital Dr. Sotero Del Rio, Santiago, Chile
4 Hospital Dr. Sotero Del Rio. Instituto De Ingenieria Biologica Y Medica/Pontificia Universidad Católica De Chile, Santiago, Chile
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2024 Annual Meeting of the ALEH

More info
Conflict of interest

No

Introduction and Objectives

Hypothermic machine perfusion using ECMO devices has emerged as a promising technique to enhance the viability of marginal liver grafts. This study aims to present the clinical outcomes of a series of 100 liver grafts subjected to this advanced preservation methods.

Patients / Materials and Methods

A prospective analysis between October 2022 and May 2024 was conducted on 100 consecutive liver perfusion cases involving hypothermic perfusion with an ECMO device, followed by a subgroup comparison of regular and marginal grafts. Post-transplantation, key outcomes such as liver functionality, early complications, and overall survival were monitored in all patients. Statistical analyses included T-tests and Fisher's exact tests to evaluate differences in means and frequencies between groups.

Results and Discussion

Three grafts were discarded due to severe steatosis. The patient cohort had a mean MELD Na score of 29.0 ± 8.72. The one-year survival rate was 82.7%. The major complication was infectious, observed in 57.7% of cases. The mean ICU and hospital stay was 10.98 ± 14.29 and 28.24 ± 24.78 days, respectively. Eighty-one liver grafts were categorized as regular (83.5%) and 16 as marginal (16.4%). Vascular complications were significantly more frequent in marginal grafts compared to regular grafts. No statistically significant differences in other clinical outcomes were observed between the regular and marginal graft groups (Table 1).

Conclusions

The findings suggest that hypothermic perfusion using ECMO devices facilitates the safe utilization of marginal liver grafts. While the overall clinical outcomes are promising and comparable to international standards, the high incidence of infectious complications and extended ICU and hospital stays highlight significant areas for improvement. These challenges appear to be more related to the severity of the patient's conditions, as indicated by the elevated average MELD Na score, rather than the quality of the grafts. Therefore, hypothermic perfusion represents a viable strategy for expanding liver graft selection criteria in transplantation.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2023.100936
No mostrar más